Background: Reverse transcription-PCR (RT-PCR) amplification of melanoma cell-specific mRNA can detect melanoma cells in the peripheral blood of patients with malignant melanoma. We present a method to quantify mRNA coding for the melanoma-specific melanoma antigen recognized by T cells #1 (MART-1) in RNA isolated from peripheral blood. Methods: To establish a calibration curve, we measured the concentration of MART-1 mRNA in SK-MEL-28 melanoma cells grown in vitro by competitive RT-PCR. Serial dilutions of these cells were used as calibrators in the assay. The assay was conducted by adding a fixed amount of a RNA internal standard to RNA isolated from either peripheral blood or the calibrators before RT-PCR amplification with MART-1 primers in a nested PCR design. The amount of MART-1 mRNA in blood samples was calculated from the calibration curve. Results: Addition of melanoma cells grown in vitro to blood from healthy donors demonstrated that the method can detect a single SK-MEL-28 melanoma cell in 1 mL of blood (1.5 ؋ 10 ؊21 mol MART-1 mRNA/mL). MART-1 mRNA was observed in 4 of 12 blood samples from patients with malignant melanoma, at concentrations of 3-18 ؋ 10 ؊21 mol MART-1 mRNA/mL of blood. No MART-1 mRNA was detected in blood samples from 25 controls without malignant melanoma. Intra-and interassay CVs were 15% (n ‫؍‬ 12; mean ‫؍‬ 44 ؋ 10 ؊21 mol MART-1 mRNA/mL) and 33% (15 samples analyzed in two different analytical runs; mean ‫؍‬ 30 ؋ 10 ؊21 mol MART-1 mRNA/mL), respectively. Conclusions: Our method is the first competitive RT-PCR assay for quantification of melanoma cells in blood samples that compensates for the variation of both the reverse transcription and PCR reactions. The method allows the inclusion of control samples for continuous quality assessment.
Malignant melanoma accounts for ϳ2% of malignant tumors and represents one of the cancer forms with the highest increase in incidence rate. The prognosis of the primary tumor usually is determined by histopathological examinations, but there is increasing interest in the development of additional prognostic markers. New methods that detect circulating cancer cells by reverse transcription-PCR (RT-PCR) have emerged for several cancer forms, including malignant melanoma (1 ), prostate cancer (2 ) , breast cancer (3 ) , and hematopoietic malignancies (4 ) . The basis of the technology is the identification of specific mRNA molecules, which are present in the circulating tumor cells but absent in nonmalignant cells of the peripheral blood. Tyrosinase mRNA is the most extensively studied marker for detection of malignant melanoma cells in peripheral blood, although other markers have been described (5 ) . Recently, melanoma antigen recognized by T cells #1 (MART-1) has been suggested as a potential marker for malignant melanoma cells in the blood (6 -8 ) . MART-1 was identified as the target of cytotoxic T lymphocytes from patients with malignant melanoma (9 ) . The gene for MART-1 has been cloned (10, 11 ) , but the cellular function of the protein is still unknown.
A major problem in detecting circulating cancer cells is the difficulty in performing reliable quantitative assays for mRNA by nested RT-PCR, because of the high degree of variation in both the reverse transcription and the PCR.
We have developed a quantitative nested RT-PCR for measurement of MART-1 in peripheral blood. By combining the use of a RNA internal standard with the use of a calibration curve, we have obtained an assay that allows us to compensate for variations in both the reverse transcription and the PCR. At the same time, only minute amounts of RNA are required for quantification of MART-1 mRNA in peripheral blood.
Materials and Methods cell culture
SK-MEL-28 cells were obtained from the American Type Culture Collection and grown in DMEM supplemented with 100 mL/L calf serum (Life Technologies). Cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 . The cells were detached by scraping, and the number of cells was determined by counting in a Bü rker-Tü rk counting chamber. Total RNA was isolated by the Purescript method (Gentra) according to the manufacturer's instructions. The isolated RNA was redissolved in distilled water, and the concentration was determined by spectrophotometry (12 ) .
patients and blood samples
Blood samples were drawn from 12 patients with biopsyverified metastatic malignant melanoma. The patients had stage IV disease according to American Joint Committee on Cancer criteria (13 ) and were staged at the time of blood sampling with a physical examination, a computed tomography scan of the brain and abdomen, and a chest x-ray. The project was accepted by the ethics committee, and written informed consent was obtained from all patients.
The first 10 mL of blood obtained was not used for RNA extraction to avoid contamination with melanocytes. Thereafter, 10 mL of blood was collected, and 1 mL was used for RNA isolation. Total RNA was isolated by the Qiagen total RNA isolation method (Qiagen) according to the manufacturer's instructions. Purified RNA was dissolved in RNЈase-free water, and the concentration and purity were determined by spectrophotometry (GeneQuant; Pharmacia) (12 ) . A group of 25 patients without a history of malignant melanoma was used as controls.
generation of rna internal standard
The RNA internal standard was generated by PCR amplification of a spacer DNA molecule [0.6-kb EcoRI-BamHI fragment of the v-erbB oncogene, available commercially from Clontech (MIMIC)]. Amplification was performed with two composite primers (Std.1 and Std.2). The composition of the Std.1 and Std.2 primers and their annealing to the spacer DNA sequence are shown in Fig. 1A . The Std.1 primer consists of a region at its 3Ј end that hybridizes to the spacer DNA, followed by regions containing the sequences of the MART-1 sense primers M1 and nested sense primer M3. At the 5Ј end of the Std.1 primer, there is a region containing the sequence of the T7 RNA polymerase promoter. The Std.2 primer consists of a 3Ј end that hybridizes to the spacer DNA, followed by the MART-1 antisense primers M2 and nested antisense primer M4, and a stretch of 20 (dT) nucleotides at the 5Ј end.
The spacer DNA fragment (1 ng) was incubated with 10 pmol of each of the Std.1 and Std.2 primers in a reaction composed of 1.5 mmol/L MgCl 2 , 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 9.0), 1 mmol/L each of the four deoxynucleotides, and 1.25 U of Taq DNA polymerase (all reagents from Perkin-Elmer) in a total reaction volume of 25 L. The PCR was performed in a Perkin-Elmer 9700 Thermal Cycler with the following cycle (A), the Std.1 and Std.2 primers were annealed to a 0.6-kb BamHI fragment of the v-erb oncogene by sequences at the 3Ј end of the primers (Hyb. Seq.). The Std.1 primer also contained the gene-specific primer sequences for the MART-1-specific M1 and M3 primers. At the 5Ј end of the Std.1 primer was located the promoter sequence of T7 RNA polymerase. The Std.2 primer contained the MART-1-specific M2 and M4 primer sequences as well as a stretch of 20 (dT) nucleotides. A DNA molecule was generated by PCR that included the sequences of the two primers. In vitro transcription with T7 RNA polymerase produced the RNA molecule to be used as RNA internal standard. (B), MART-1 mRNA and RNA internal standard were reverse-transcribed with an oligo(dT) primer (open arrows). A PCR product was formed with the M1 and M2 primers (1. Round PCR, solid arrows) in the first round of PCR. Subsequently, a nested PCR reaction was conducted with the M3 and M4 primers (2. Round PCR, solid arrows).
conditions: 94°C for 1 min, 57°C for 30 s, 72°C for 90 s. Initially, the PCR reaction was heated to 94°C for 3 min. After 25 cycles of PCR amplification, the reaction was incubated at 72°C for 7 min. The PCR products were checked by agarose gel electrophoresis, and the presence of a single band of the correct size was demonstrated. RNA internal standard was generated by incubation of the obtained PCR product (1 g) with 40 U of T7 RNA polymerase at 37°C for 2 h in the buffer supplied by the manufacturer (Boehringer Mannheim). The DNA was removed by treatment with 10 U of RNЈase-free DNЈase I (Promega) for 15 min at 37°C in Multicore buffer (Promega). The reaction was extracted with 1 volume of water-saturated phenol:chloroform (99:1 by volume), and the water phase containing the RNA was precipitated by the addition of 2.5 volumes of 960 mL/L ethanol and 1/10 volume of 4 mol/L NaCl. The sample was placed at Ϫ20°C for 30 min and centrifuged for 15 min at 20 800g in an Eppendorf centrifuge. The pellet was washed with 1 mL of 700 mL/L ethanol, dried, and redissolved in 100 L of distilled water. The RNA was quantified by absorbance at 260 nm (12 ) . The absence of DNA in the RNA internal standard was demonstrated by the inability to produce PCR products in the absence of reverse transcription.
competitive rt-pcr quantification of mart-1 mRNA in calibrators Calibrators for MART-1 mRNA quantification were obtained from a RNA stock solution isolated from 10 000 SK-MEL-28 cells added to 1 mL of MART-1-negative blood from a healthy individual. The concentrations of MART-1 mRNA in the calibrators were determined by competitive RT-PCR. This was performed by combining serial dilutions of the RNA internal standard with the calibrator RNA followed by RT-PCR amplification under the conditions described below. Plotting the ratio of the MART-1:internal standard band intensities against the concentration of the internal standard added made it possible to determine the MART-1 concentration in the calibrator as the internal standard concentration where equal amounts of RT-PCR products were generated from the internal standard and the calibrator (14, 15 ) .
quantitative rt-pcr
The calibrated RT-PCR method for MART-1 mRNA quantification was performed by a modification of the procedure described previously for the epidermal growth factor receptor (14 ) . Briefly, a fixed amount (4.3 ϫ 10 Ϫ22 mol) of RNA internal standard was added to the RNA samples and to each of the calibrators in a reverse transcription reaction consisting of 10 mmol/L Tris-HCl (pH 8.3), 6.25 mmol/L MgCl 2 , 50 mmol/L KCl, 1 unit/L RNЈase inhibitor, 1 mmol/L deoxyribonucleoside triphosphates (dATP, dCTP, dTTP, and dGTP), 2.5 mmol/L 16-mer oligo(dT) primer, and 2.5 U of reverse transcriptase (all reaction components were from Perkin-Elmer) in a total volume of 20 L. The reaction mixture was incubated at 42°C for 30 min in a Perkin-Elmer 9700 thermocycler, and 2.5 L of the resulting cDNA product was PCR-amplified with 1.25 U of Taq DNA polymerase (Pharmacia) and 10 pmol of each of the M1 and M2 primers in a buffer containing 10 mmol/L Tris-HCl (pH 9.0), 1.5 mmol/L MgCl 2, 50 mmol/L KCl, and 0.2 mmol/L deoxyribonucleoside triphosphates (dATP, dCTP, dTTP, and dGTP). The sequence of the M1 and M2 primers were 5Ј-GAAGGTGTCCTGTGCCCTGACCC-3Ј and 5Ј-GGCTT-GCATTTTTCCTACACCATTCC-3Ј, respectively. The primers spanned intron sequences, thereby ensuring that no genomic DNA was amplified. Samples were subjected to PCR amplification in a Perkin-Elmer 9700 thermocycler with the following profile: 94°C for 1 min, 57°C for 30 s, and 72°C for 90 s. After 40 cycles, the PCR products were extended at 72°C for 7 min. All reactions were initially denatured at 94°C for 3 min before PCR amplification. After amplification, 2.5 L of the PCR product was used as template in the nested PCR reaction using the M3 and M4 primers (10 pmol each), which had the sequences 5Ј-ATGC-CAAGAGAAGATGCT-3Ј and 5Ј-GGAGAACATTAGAT-GTCTG-3Ј, respectively. The nested-PCR buffer and other conditions were the same as for the primary PCR. A PCR reaction of 30 cycles was performed with an amplification profile of 99°C for 1 min, 57°C for 30 s, and 72°C for 90 s. Finally. the PCR products were extended at 72°C for 7 min. The reactions were analyzed on a 2% agarose gel stained with ethidium bromide. The intensity of the bands was determined by computer scanning (Gel doc 1000; Bio-Rad), and the intensities of the bands were corrected for the difference in size between the PCR products originating from the RNA internal standard (317 bp) and the MART-1 mRNA (440 bp). The identity of the PCR products was verified by sequencing (BigDye terminator chemistry and an ABI Prism 310 Genetic Analyzer; Perkin-Elmer).
Results

rt-pcr amplification of mart-1 mRNA
The design of the nested RT-PCR assay is outlined in Fig.  1B . MART-1 mRNA and the RNA internal standard were amplified by reverse transcription followed by two rounds of PCR amplification using two sets of MART-1specific primers as outlined in Fig. 1B . Two rounds of PCR were necessary because no MART-1 RT-PCR product could be detected when only a single round of PCR was performed. The RNA internal standard was RT-PCRamplified with the same primer sets and in the same reaction tube as the MART-1 mRNA (Fig. 1B) . Nested RT-PCR amplification of MART-1 mRNA from RNA corresponding to 10 SK-MEL-28 cells produced a single band with a size of 440 bp (Fig. 2A, lane 1) . When the RNA internal standard was used as template, a PCR product migrating to the expected position (317 bp) was generated ( Fig. 2A, lane 2) .
generation of calibrator rna
SK-MEL-28 cells (10 000) diluted in 1 mL of MART-1 mRNA-negative blood were used to prepare the calibrators. The concentration of MART-1 mRNA in the calibrator was determined by competitive RT-PCR. Calibrator RNA diluted to a concentration corresponding to 10 SK-MEL-28 cells was mixed with serial dilutions of RNA internal standard followed by reverse transcription and MART-1-specific nested PCR (Fig. 2B, lanes 1-6) . The intensities of the bands were determined, and the ratio between the PCR products from the MART-1 mRNA and RNA internal standard in each lane was plotted against the concentration of the RNA internal standard added ( Fig. 2C ; mean value of four independent experiments). The MART-1 mRNA in the calibrator RNA was calculated as the RNA internal standard concentration, where equal amounts of PCR products of the two types were generated (ratio equal to 1, corresponding to a log ratio equal to 0). The amount of MART-1 mRNA corresponding to 10 SK-MEL-28 cells was 30 ϫ 10 Ϫ23 mol in 1 L of the 50 L in which RNA from 1 mL of blood was dissolved, corresponding to 15 ϫ 10 Ϫ21 mol MART-1 RNA/mL. Equal amplification kinetics of the MART-1 mRNA and the RNA internal standard are a requirement for quantification. The amplification efficiency of the MART-1 mRNA and the internal standard RNA was investigated by a series of RT-PCR amplifications in which the number of PCR cycles in either the first or second round of the nested PCR reaction was gradually reduced. The amplification efficiencies of the MART-1 mRNA and the RNA internal standard were equal (data not shown).
quantification of mart-1 mRNA
The unknown samples and a dilution series of the calibrator RNA covering the range 1.5-150 ϫ 10 Ϫ21 mol of MART-1 mRNA/mL were incubated with RNA internal standard, and the nested MART-1 RT-PCR reaction was performed. In our assay design, RNA from 1 mL of calibrator or sample was dissolved in 50 L of buffer, and 1 L was used for RT-PCR. Thus, in absolute amounts the calibrators ranged from 1.5 ϫ 10 Ϫ21 to 150 ϫ 10 Ϫ21 mol of MART-1 mRNA/mL. Reaction products were separated by gel electrophoresis, and the intensities of the DNA bands originating from the MART-1 mRNA and the RNA internal standard were quantified. Fig. 3 shows the resulting calibration curve. The amount of MART-1 mRNA present in the individual unknown samples could be determined from the calibration curve. The point on the calibration curve with the lowest amount of SK-MEL-28 RNA added corresponded to 1 cell/mL of blood. The intraassay imprecision (CV) was 15% (n ϭ 12; mean, 44 ϫ 10 Ϫ21 mol MART-1 mRNA/mL), and the interassay CV was 33% (15 samples analyzed on two occasions; mean, 30 ϫ 10 Ϫ21 mol MART-1 mRNA/mL).
quantification of mart-1 mRNA in blood from patients with malignant melanoma and controls RNA was isolated from blood samples obtained from 12 patients with metastatic melanoma and from the 25 controls. The purified RNA was subjected to the quantitative MART-1 mRNA assay. MART-1 mRNA was found in 4 of the 12 patients (33%). The MART-1 mRNA concentrations observed in the four patients were 3, 3, 12, and 18 ϫ 10 Ϫ21 mol MART-1 mRNA/mL of blood. Table 1 presents the clinical data of the patients. No MART-1 mRNA was found in any of the 25 controls.
Discussion
Detection of circulating cancer cells in the peripheral blood of cancer patients by identification of tumor-specific mRNA is a rapidly emerging new technology. The method has been used to detect cancer cells in blood from patients with various cancers, such as malignant melanoma, prostate cancer, and breast cancer, as reviewed by Pelkey et al. (16 ) . The most commonly used method is RT-PCR amplification of mRNA molecules that are expressed exclusively by cancer cells and thus are absent from blood of healthy donors. However, a major problem in detecting, and particularly in quantifying, the mRNA is the high degree of variation typically observed for both the PCR and reverse transcription reactions (17 ) . To solve these problems, refined quantitative methods are required.
In the present study, we developed a technique for quantification of MART-1 mRNA in RNA from peripheral blood samples. In this method, RNA is purified from the blood sample, and a known concentration of a RNA internal standard is added. The RNA internal standard is coamplified with the same kinetics as the MART-1 mRNA present in the blood sample. The concentration of MART-1 mRNA in the melanoma cell line SK-MEL-28 was determined, which enabled us to use serial dilutions of this RNA as calibrators for the generation of a calibration curve. Compared with competitive RT-PCR, where several concentrations of RNA standard are used for each unknown RNA sample, this method has the advantage of requiring only a single RT-PCR for each sample, thereby saving time and sample material. In addition, the method allows the inclusion of RNA samples with known amounts of MART-1 mRNA for quality control. A linear calibration curve was observed for 1.5-150 ϫ 10 Ϫ21 mol of MART-1 mRNA (1-100 SK-MEL-28 melanoma cells). Samples containing a higher number of cells could be quantified by dilution of the sample RNA. The method had an intraassay CV of 15% and an interassay CV of 33%. Most studies have included DNA calibrators for quantification of circulating cancer cells, and to our knowledge, the method presented here is the first that takes advantage of a RNA internal standard for quantification of circulating melanoma cells. A RNA internal standard was also used for detection of circulating breast cancer cells and prostate cancer cells in two recent studies (18, 19 ) . The major advantage of the RNA internal standard is the ability to control both the reverse transcription reaction and the PCR reaction.
Data from the analysis of blood samples from patients with malignant melanoma demonstrated the ability of our method to quantify the MART-1 mRNA found in patient samples. We found that 4 of 12 patients (33%) with malignant melanoma contained MART-1 mRNA in the blood in concentrations of 3-18 ϫ 10 Ϫ21 mol MART-1 mRNA/mL. In contrast, no MART-1 mRNA was detected in the controls.
Tyrosinase mRNA is the marker used most extensively for the detection of circulating melanoma cells. Other mRNA markers (MART-1, MUC18, and p97) have also been shown to have a potential in detecting these cells (7 ) .
Recent studies have demonstrated that inclusion of more than one marker increases the probability of detecting the circulating cancer cells (6 ) . At present, the clinical significance of detecting circulating malignant melanoma cells is under investigation. Several investigators have reported on the prognostic value of the method (5, 7, 8, 20 ) . However, other investigators have questioned the use of RT-PCR detection of circulating melanoma cells using tyrosinase as a marker because large differences in sensitivity have been reported between different laboratories (21, 22 ) . Some of these differences might be explained by differences in the RT-PCR amplification procedures used in the different laboratories. The method presented here might be useful in generating more reliable quantitative data on the presence of cancer cells in the blood of patients.
